What's Happening?
American Airlines has announced a significant change to its healthcare plan for flight attendants, effective January 1, 2026. The airline will no longer cover GLP-1 medications, such as Ozempic, for weight loss unless the employee has type 2 diabetes.
This decision has sparked frustration among the flight attendants' union, the Association of Professional Flight Attendants (APFA), which argues that many members rely on these medications for weight management. The union has proposed alternatives like copay caps and prior authorization requirements to maintain access to these drugs while managing costs. However, American Airlines has opted for outright exclusion, citing financial constraints.
Why It's Important?
This healthcare policy change by American Airlines could have significant implications for its flight attendants, many of whom use Ozempic for weight management. The exclusion of this medication from coverage may lead to increased out-of-pocket expenses for employees, as the retail cost of Ozempic is approximately $1,000 per month. This decision reflects broader challenges in balancing healthcare costs and employee benefits, particularly in industries with high labor costs like aviation. The move may also influence other airlines' healthcare policies, potentially affecting a large number of employees across the sector.
What's Next?
The flight attendants' union plans to continue advocating for the inclusion of Ozempic in the healthcare plan, urging members to voice their concerns to American Airlines management. The outcome of these efforts could set a precedent for future negotiations on employee healthcare benefits in the airline industry. Additionally, the financial health of American Airlines and its ability to manage labor costs will likely be closely monitored by industry analysts and stakeholders.
